

Kamilla Miskowiak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8412684/kamilla-miskowiak-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

3,750
citations

36
h-index

55
g-index

194
ext. papers

5,029
ext. citations

5.4
avg, IF

5.85
L-index

#	Paper	IF	Citations
176	Impaired allocentric spatial memory in patients with affective disorders.. <i>Journal of Psychiatric Research</i> , 2022 , 150, 153-159	5.2	0
175	Associations between cognition and subsequent mood episodes in patients with bipolar disorder and their unaffected relatives: A systematic review. <i>Journal of Affective Disorders</i> , 2022 , 297, 176-188	6.6	0
174	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015-2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.. <i>Bipolar Disorders</i> , 2022 ,	3.8	2
173	Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: Pattern, severity, and functional implications.. <i>European Neuropsychopharmacology</i> , 2022 , 59, 82-92	1.2	1
172	Neural underpinnings of emotion regulation subgroups in remitted patients with recently diagnosed bipolar disorder.. <i>European Neuropsychopharmacology</i> , 2022 , 60, 7-18	1.2	0
171	Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811221089035	4.6	1
170	Reduced frontostriatal response to expected value and reward prediction error in remitted monozygotic twins with mood disorders and their unaffected high-risk co-twins. <i>Psychological Medicine</i> , 2021 , 51, 1637-1646	6.9	3
169	Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects: challenges, opportunities, and next steps. <i>CNS Spectrums</i> , 2021 , 26, 333-337	1.8	6
168	Cognition Assessment in Virtual Reality: Validity and feasibility of a novel virtual reality test for real-life cognitive functions in mood disorders and psychosis spectrum disorders.. <i>Journal of Psychiatric Research</i> , 2021 , 145, 182-189	5.2	1
167	Childhood diagnoses in individuals identified as autistics in adulthood.. <i>Molecular Autism</i> , 2021 , 12, 73	6.5	2
166	Action-based cognitive remediation in bipolar disorder improved verbal memory but had no effect on the neural response during episodic memory encoding. <i>Psychiatry Research - Neuroimaging</i> , 2021 , 319, 111418	2.9	
165	Fatigue and Cognitive Impairment in Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis.. <i>Brain, Behavior, and Immunity</i> , 2021 ,	16.6	60
164	Influence of pre-treatment structural brain measures on effects of action-based cognitive remediation on executive function in partially or fully remitted patients with bipolar disorder.. <i>European Neuropsychopharmacology</i> , 2021 , 56, 50-59	1.2	
163	Cognitive Adverse Effects of Electroconvulsive Therapy: A Discrepancy Between Subjective and Objective Measures?. <i>Journal of ECT</i> , 2021 ,	2	1
162	Reduced prefrontal cortex response to own vs. unknown emotional infant faces in mothers with bipolar disorder. <i>European Neuropsychopharmacology</i> , 2021 , 54, 7-20	1.2	0
161	Effect of Action-Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: A randomized controlled trial. <i>Bipolar Disorders</i> , 2021 , 23, 487-499	3.8	10
160	Recognising the relevance of cognitive dysfunction in the clinical management of bipolar disorder. <i>Bipolar Disorders</i> , 2021 , 23, 414-415	3.8	2

159	Affective and non-affective cognition in patients with bipolar disorder type I and type II in full or partial remission: Associations with familial risk. <i>Journal of Affective Disorders</i> , 2021 , 283, 207-215	6.6	1
158	Processing of infant emotion in mothers with mood disorders and implications for infant development. <i>Psychological Medicine</i> , 2021 , 1-11	6.9	3
157	Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1470-1471	27.4	
156	Assessment of the neuronal underpinnings of cognitive impairment in bipolar disorder with a picture encoding paradigm and methodological lessons learnt. <i>Journal of Psychopharmacology</i> , 2021 , 35, 983-991	4.6	1
155	Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients. <i>ERJ Open Research</i> , 2021 , 7,	3.5	14
154	Evaluating endophenotypes for bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2021 , 9, 17	5.4	4
153	Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. <i>European Neuropsychopharmacology</i> , 2021 , 46, 39-48	1.2	59
152	Social cognition in bipolar disorder: A proxy of psychosocial function and novel treatment target?. <i>European Neuropsychopharmacology</i> , 2021 , 46, 37-38	1.2	3
151	Neuronal underpinnings of cognitive impairment in bipolar disorder: A large data-driven functional magnetic resonance imaging study. <i>Bipolar Disorders</i> , 2021 ,	3.8	2
150	Neuronal and cognitive predictors of improved executive function following action-based cognitive remediation in patients with bipolar disorder. <i>European Neuropsychopharmacology</i> , 2021 , 47, 1-10	1.2	4
149	Internet-based cognitive assessment tool: Sensitivity and validity of a new online cognition screening tool for patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2021 , 289, 125-134	6.6	3
148	Cognitive training with fully immersive virtual reality in patients with neurological and psychiatric disorders: A systematic review of randomized controlled trials. <i>Psychiatry Research</i> , 2021 , 300, 113928	9.9	14
147	Hippocampal subfield morphology in monozygotic twins discordant for affective disorders. <i>Neuropsychopharmacology</i> , 2021 , 46, 561-568	8.7	2
146	Cognitive processing of infant stimuli in pregnant women with and without affective disorders and the association to postpartum depression. <i>European Neuropsychopharmacology</i> , 2021 , 42, 97-109	1.2	2
145	Effects of psychological and pharmacological interventions on anxiety symptoms in patients with bipolar disorder in full or partial remission: A systematic review. <i>Journal of Affective Disorders</i> , 2021 , 279, 31-45	6.6	3
144	Virtual reality assessment of daily life executive functions in mood disorders: associations with neuropsychological and functional measures. <i>Journal of Affective Disorders</i> , 2021 , 280, 478-487	6.6	6
143	Change in prefrontal activity and executive functions after action-based cognitive remediation in bipolar disorder: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2021 , 46, 1113-1121	8.7	4
142	Norms for the Screen for Cognitive Impairment in Psychiatry and cognitive trajectories in bipolar disorder. <i>Journal of Affective Disorders</i> , 2021 , 281, 33-40	6.6	9

141	Residual Anxiety in Patients with Bipolar Disorder in Full or Partial Remission: Metacognitive Beliefs and Neurocognitive Function. <i>Cognitive Therapy and Research</i> , 2021 , 45, 179-189	2.7	1
140	The impact of the trajectory of bipolar disorder on global cognitive function: A one-year clinical prospective case-control study. <i>Journal of Affective Disorders</i> , 2021 , 278, 189-198	6.6	2
139	Neurocognitive heterogeneity in patients with bipolar disorder and their unaffected relatives: associations with emotional cognition. <i>Psychological Medicine</i> , 2021 , 51, 668-679	6.9	10
138	Neurocognitive processing of infant stimuli in mothers and non-mothers: psychophysiological, cognitive and neuroimaging evidence. <i>Social Cognitive and Affective Neuroscience</i> , 2021 , 16, 428-438	4	
137	Hippocampal neurons respond to brain activity with functional hypoxia. <i>Molecular Psychiatry</i> , 2021 , 26, 1790-1807	15.1	7
136	P.319 Cognitive predictors of mood episodes in patients newly diagnosed with bipolar disorder. <i>European Neuropsychopharmacology</i> , 2021 , 44, S52-S53	1.2	
135	Structural brain abnormalities associated with cognitive impairments in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 144, 379-391	6.5	0
134	Autism comorbidities show elevated female-to-male odds ratios and are associated with the age of first autism diagnosis. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 144, 475-486	6.5	3
133	Affective disorders impact prevalence of Flavonifractor and abundance of Christensenellaceae in gut microbiota. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 110, 110300	5.5	3
132	Screening for cognitive impairment among patients with work-related stress complaints in Denmark: validation and evaluation of objective and self-report tools. <i>Scandinavian Journal of Work, Environment and Health</i> , 2021 ,	4.3	2
131	Addressing the Hypoxia paradox in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. <i>Molecular Medicine</i> , 2021 , 27, 120	6.2	2
130	Emotional cognition subgroups in mood disorders: Associations with familial risk. <i>European Neuropsychopharmacology</i> , 2021 , 51, 71-83	1.2	3
129	Affective episodes in recently diagnosed patients with bipolar disorder associated with altered working memory-related prefrontal cortex activity: A longitudinal fMRI study. <i>Journal of Affective Disorders</i> , 2021 , 295, 647-656	6.6	1
128	P.0278 Structural brain abnormalities associated with cognitive impairments in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2021 , 53, S201	1.2	
127	P.0717 Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives. <i>European Neuropsychopharmacology</i> , 2021 , 53, S524-S525	1.2	
126	P.0720 Cognition assessment in virtual reality: training of real-life cognitive functions with fully immersive virtual reality in mood or psychotic disorders. <i>European Neuropsychopharmacology</i> , 2021 , 53, S527-S528	1.2	
125	Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial. <i>Journal of Psychiatry and Neuroscience</i> , 2020 , 45, 198-205	4.5	5
124	Erythropoietin in Preterm Infants. <i>New England Journal of Medicine</i> , 2020 , 382, 1862	59.2	3

123	S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. <i>Journal of Affective Disorders</i> , 2020 , 274, 726-732	6.6	2
122	Identifying social cognition subgroups in euthymic patients with bipolar disorder: a cluster analytical approach. <i>Psychological Medicine</i> , 2020 , 1-10	6.9	7
121	Erythropoietin as candidate for supportive treatment of severe COVID-19. <i>Molecular Medicine</i> , 2020 , 26, 58	6.2	26
120	Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin. <i>Nature Communications</i> , 2020 , 11, 1313	17.4	31
119	Eye gaze and facial displays of emotion during emotional film clips in remitted patients with bipolar disorder. <i>European Psychiatry</i> , 2020 , 63, e29	6	2
118	The effect of erythropoietin on electroconvulsive stimulation induced cognitive impairment in rats. <i>Behavioural Brain Research</i> , 2020 , 382, 112484	3.4	1
117	Women With Borderline Personality Disorder Show Reduced Identification of Emotional Facial Expressions and a Heightened Negativity Bias. <i>Journal of Personality Disorders</i> , 2020 , 34, 677-698	2.6	8
116	Effects of Dihydroxybutyrate on cognition in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2020 , 182, 233-242	6.5	11
115	Patient-evaluated cognitive function measured with smartphones and the association with objective cognitive function, perceived stress, quality of life and function capacity in patients with bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2020 , 8, 31	5.4	1
114	Understanding familial liability for emotion regulation difficulties in bipolar disorder. <i>Psychological Medicine</i> , 2020 , 1-8	6.9	4
113	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? - a monozygotic twin study. <i>Psychological Medicine</i> , 2020 , 50, 1736-1745	6.9	6
112	P.218 Social cognition in bipolar disorder: a cluster analysis. <i>European Neuropsychopharmacology</i> , 2020 , 31, S32	1.2	
111	Aberrant cognition in newly diagnosed patients with bipolar disorder and their unaffected relatives. <i>Psychological Medicine</i> , 2020 , 50, 1808-1819	6.9	11
110	Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. <i>Bipolar Disorders</i> , 2020 , 22, 13-27	3.8	42
109	Abnormal prefrontal cortex processing of reward prediction errors in recently diagnosed patients with bipolar disorder and their unaffected relatives. <i>Bipolar Disorders</i> , 2020 , 22, 849-859	3.8	2
108	The maternal brain: Neural responses to infants in mothers with and without mood disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 107, 196-207	9	17
107	Characteristics influencing expected cognitive performance during hypoglycaemia in type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2019 , 110, 104431	5	3
106	Is aberrant affective cognition an endophenotype for affective disorders? - A monozygotic twin study. <i>Psychological Medicine</i> , 2019 , 49, 987-996	6.9	11

105	Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial. <i>Diabetologia</i> , 2019 , 62, 1948-1958	10.3	11
104	Whole-Brain Exploratory Analysis of Functional Task Response Following Erythropoietin Treatment in Mood Disorders: A Supervised Machine Learning Approach. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1246	5.1	0
103	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. <i>Bipolar Disorders</i> , 2019 , 21, 686-719	3.8	36
102	Neural response to emotional faces in monozygotic twins: association with familial risk of affective disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2019 , 44, 277-286	4.5	4
101	The Internet-Based Cognitive Assessment Tool: System Design and Feasibility Study. <i>JMIR Formative Research</i> , 2019 , 3, e13898	2.5	10
100	The BDNF Val66Met Polymorphism Has No Effect on Encoding-Related Hippocampal Response But Influences Recall in Remitted Patients With Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2019 , 10, 845	5	1
99	Emotional Mental Imagery Abnormalities in Monozygotic Twins With, at High-Risk of, and Without Affective Disorders: Present in Affected Twins in Remission but Absent in High-Risk Twins. <i>Frontiers in Psychiatry</i> , 2019 , 10, 801	5	2
98	Neuronal underpinnings of cognitive impairment and - improvement in mood disorders. <i>CNS Spectrums</i> , 2019 , 24, 30-53	1.8	17
97	Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. <i>Journal of Affective Disorders</i> , 2019 , 246, 763-774	6.6	40
96	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 154-162	1.8	9
95	Neural response during emotion regulation in monozygotic twins at high familial risk of affective disorders. <i>NeuroImage: Clinical</i> , 2019 , 21, 101598	5.3	27
94	Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2019 , 29, 319-329 ^{1.2}	1.2	21
93	Remitted affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota. <i>Acta Psychiatrica Scandinavica</i> , 2019 , 139, 174-184	6.5	25
92	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019 , 53, 651-662	2.6	21
91	Bipolar disorders. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18008	51.1	289
90	Increased sensitivity to positive social stimuli in monozygotic twins at risk of bipolar vs. unipolar disorder. <i>Journal of Affective Disorders</i> , 2018 , 232, 212-218	6.6	9
89	Glycogen synthase kinase-3 β activity and cognitive functioning in patients with bipolar I disorder. <i>European Neuropsychopharmacology</i> , 2018 , 28, 361-368	1.2	4
88	Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. <i>Bipolar Disorders</i> , 2018 , 20, 184-194	3.8	87

87	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018 , 19, 234	2.8	3
86	Design and Implementation of a Web-based Application to Assess Cognitive Impairment in Affective Disorder 2018 ,		2
85	Erythropoietin prevents the effect of chronic restraint stress on the number of hippocampal CA3c dendritic terminals-relation to expression of genes involved in synaptic plasticity, angiogenesis, inflammation, and oxidative stress in male rats. <i>Journal of Neuroscience Research</i> , 2018 , 96, 103-116	4.4	9
84	Is negative self-referent bias an endophenotype for depression? An fMRI study of emotional self-referent words in twins at high vs. low risk of depression. <i>Journal of Affective Disorders</i> , 2018 , 226, 267-273	6.6	4
83	Towards a biomarker model for cognitive improvement: No change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1075-1085	4.6	9
82	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2018 , 8, e019562	3	16
81	Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018 , 9, 337	5	18
80	Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 138, 336-347	6.5	1
79	Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders. <i>Acta Neuropsychiatrica</i> , 2018 , 30, 342-349	3.9	7
78	Effect of electroconvulsive therapy on neural response to affective pictures: A randomized, sham-controlled fMRI study. <i>European Neuropsychopharmacology</i> , 2018 , 28, 915-924	1.2	7
77	Unravelling the GSK3 β -related genotypic interaction network influencing hippocampal volume in recurrent major depressive disorder. <i>Psychiatric Genetics</i> , 2018 , 28, 77-84	2.9	23
76	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018 , 19, 611	2.8	7
75	Does Cognitive Dysfunction in Bipolar Disorder Qualify as a Diagnostic Intermediate Phenotype?-A Perspective Paper. <i>Frontiers in Psychiatry</i> , 2018 , 9, 490	5	13
74	Clinical Characteristics, Life Adversities and Personality Traits in Monozygotic Twins With, at Risk of and Without Affective Disorders. <i>Frontiers in Psychiatry</i> , 2018 , 9, 401	5	8
73	GSK3 α plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?. <i>Translational Psychiatry</i> , 2018 , 8, 216	8.6	11
72	Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2018 , 19, 487	2.8	15
71	Subtle behavioural responses during negative emotion reactivity and down-regulation in bipolar disorder: A facial expression and eye-tracking study. <i>Psychiatry Research</i> , 2018 , 266, 152-159	9.9	14
70	Imaging genetics paradigms in depression research: Systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 86, 102-113	5.5	11

69	Neural Response After a Single ECT Session During Retrieval of Emotional Self-Referent Words in Depression: A Randomized, Sham-Controlled fMRI Study. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 226-235	5.8	5
68	Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study. <i>Psychiatry Research</i> , 2017 , 249, 268-274	9.9	11
67	Cognitive Impairment in Euthymic Pediatric Bipolar Disorder: A Systematic Review and Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017 , 56, 286-296	7.2	46
66	Differences in neural and cognitive response to emotional faces in middle-aged dizygotic twins at familial risk of depression. <i>Psychological Medicine</i> , 2017 , 47, 2345-2357	6.9	7
65	The relationship between genetic risk variants with brain structure and function in bipolar disorder: A systematic review of genetic-neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 79, 87-109	9	17
64	The catechol-O-methyltransferase (COMT) Val158Met genotype modulates working memory-related dorsolateral prefrontal response and performance in bipolar disorder. <i>Bipolar Disorders</i> , 2017 , 19, 214-224	3.8	41
63	Does a single session of electroconvulsive therapy alter the neural response to emotional faces in depression? A randomised sham-controlled functional magnetic resonance imaging study. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1215-1224	4.6	8
62	The search for neuroimaging and cognitive endophenotypes: A critical systematic review of studies involving unaffected first-degree relatives of individuals with bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 73, 1-22	9	59
61	An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: the IMPACT study. <i>BMC Psychiatry</i> , 2017 , 17, 370	4.2	6
60	Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. <i>Bipolar Disorders</i> , 2017 , 19, 614-626	3.8	103
59	Failure to publish negative results: A systematic bias in psychiatric literature. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 212-214	2.6	8
58	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017 , 7, e0154623		81
57	Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. <i>Journal of Affective Disorders</i> , 2016 , 205, 378-386	6.6	78
56	Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 511-521	6.5	46
55	Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1845-1867	1.2	36
54	Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study. <i>Brain, Behavior, and Immunity</i> , 2016 , 57, 53-57	16.6	15
53	Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: A pilot study of a novel experimental paradigm. <i>Psychiatry Research</i> , 2016 , 238, 318-325	9.9	16
52	Bias in Peripheral Depression Biomarkers. <i>Psychotherapy and Psychosomatics</i> , 2016 , 85, 81-90	9.4	44

51	Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. <i>Journal of Affective Disorders</i> , 2016 , 190, 607-615	6.6	71
50	Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D) as outcome measure. <i>Journal of Affective Disorders</i> , 2016 , 190, 842-845	6.6	26
49	Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. <i>Journal of Psychiatry and Neuroscience</i> , 2016 , 41, 38-47	4.5	6
48	Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, e1639-e1646	4.6	24
47	Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders. <i>Acta Psychiatrica Scandinavica</i> , 2016 , 134, 249-59	6.5	21
46	Neural correlates of improved executive function following erythropoietin treatment in mood disorders. <i>Psychological Medicine</i> , 2016 , 46, 1679-91	6.9	27
45	Glycogen Synthase Kinase-3 Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. <i>Neuropsychobiology</i> , 2016 , 73, 108-15	4	4
44	Bias in emerging biomarkers for bipolar disorder. <i>Psychological Medicine</i> , 2016 , 46, 2287-97	6.9	41
43	Cognitive remission: a novel objective for the treatment of major depression?. <i>BMC Medicine</i> , 2016 , 14, 9	11.4	123
42	Cognitive enhancement treatments for bipolar disorder: A systematic review and methodological recommendations. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1541-61	1.2	57
41	The effect of erythropoietin on cognition in affective disorders - Associations with baseline deficits and change in subjective cognitive complaints. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1264-73	1.2	31
40	Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. <i>Journal of Affective Disorders</i> , 2015 , 187, 10-9	6.6	67
39	Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. <i>Psychiatry Research</i> , 2015 , 229, 565-71	9.9	49
38	Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression. <i>Psychological Medicine</i> , 2015 , 45, 1447-58	6.9	30
37	Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. <i>Biological Psychiatry</i> , 2015 , 78, 270-7	7.9	65
36	The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study. <i>PLoS ONE</i> , 2015 , 10, e0127629	3.7	14
35	Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. <i>PLoS ONE</i> , 2015 , 10, e0127955	3.7	72
34	Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. <i>Neuropsychiatric Disease and Treatment</i> , 2015 , 11, 3111-25	3.1	133

33	Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2289-99	1.2	7
32	Cognitive dysfunction in depression - pathophysiology and novel targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1819-35	2.6	66
31	Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. <i>Neuropsychopharmacology</i> , 2014 , 39, 1399-408	8.7	72
30	Brain Derived Neurotrophic Factor (BDNF) levels as a possible predictor of psychopathology in healthy twins at high and low risk for affective disorder. <i>Psychoneuroendocrinology</i> , 2014 , 39, 179-183	5	8
29	A role for prostaglandins in rapid cycling suggested by episode-specific gene expression shifts in peripheral blood mononuclear cells: a preliminary report. <i>Bipolar Disorders</i> , 2014 , 16, 881-8	3.8	9
28	Serotonin transporter genotype, salivary cortisol, neuroticism and life events: impact on subsequent psychopathology in healthy twins at high and low risk for affective disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 48, 193-8	5.5	4
27	HotTcognition in major depressive disorder: a systematic review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1787-803	2.6	32
26	Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 1347-55	4.6	64
25	Risk markers for affective disorder, a seven-years follow up study of a twin cohort at low and high risk for affective disorder. <i>Journal of Psychiatric Research</i> , 2013 , 47, 565-71	5.2	21
24	Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. <i>Journal of Affective Disorders</i> , 2013 , 149, 355-62	6.6	61
23	Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2013 , 14, 378	2.8	23
22	Effects of the BDNF Val66Met polymorphism and met allele load on declarative memory related neural networks. <i>PLoS ONE</i> , 2013 , 8, e74133	3.7	7
21	Impairment of executive function and attention predicts onset of affective disorder in healthy high-risk twins. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, e747-53	4.6	25
20	Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. <i>Psychopharmacology</i> , 2012 , 219, 687-98	4.7	51
19	Acute antidepressant drug administration and autobiographical memory recall: a functional magnetic resonance imaging study. <i>Experimental and Clinical Psychopharmacology</i> , 2012 , 20, 364-72	3.2	9
18	Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. <i>Nordic Journal of Psychiatry</i> , 2012 , 66, 248-53	2.3	85
17	Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. <i>Molecular Medicine</i> , 2012 , 18, 1029-40	6.2	25
16	Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder?. <i>Nordic Journal of Psychiatry</i> , 2012 , 66, 389-95	2.3	23

15	Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. <i>Psychopharmacology</i> , 2010 , 210, 419-28	4.7	27
14	Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. <i>Trials</i> , 2010 , 11, 97	2.8	34
13	Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. <i>Psychopharmacology</i> , 2009 , 207, 133-42	4.7	38
12	P.3.11 Erythropoietin modulates emotional processing in biomarker models of antidepressant drug action in depressed patients. <i>European Neuropsychopharmacology</i> , 2009 , 19, S71-S71	1.2	
11	Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. <i>Neuropsychopharmacology</i> , 2008 , 33, 611-8	8.7	62
10	Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. <i>Experimental Brain Research</i> , 2008 , 184, 313-21	2.3	44
9	Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. <i>Biological Psychiatry</i> , 2007 , 62, 1244-50	7.9	39
8	Erythropoietin has no effect on hippocampal response during memory retrieval 3 days post-administration. <i>Psychopharmacology</i> , 2007 , 195, 451-3	4.7	10
7	Erythropoietin enhances hippocampal response during memory retrieval in humans. <i>Journal of Neuroscience</i> , 2007 , 27, 2788-92	6.6	75
6	Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. <i>NeuroImage</i> , 2007 , 37, 904-11	7.9	43
5	Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats. <i>Pharmacology Biochemistry and Behavior</i> , 2004 , 77, 381-90	3.9	41
4	A novel treatment targeting cognitive dysfunction in mood disorders 289-305		
3	Emotional cognition subgroups in unaffected first-degree relatives of patients with mood disorders. <i>Psychological Medicine</i> , 1-11	6.9	0
2	Neural responses during down-regulation of negative emotion in patients with recently diagnosed bipolar disorder and their unaffected relatives. <i>Psychological Medicine</i> , 1-12	6.9	0
1	Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review. <i>Current Treatment Options in Psychiatry</i> , 1	3.1	